CN1240392C - 促进细胞活化的外用剂 - Google Patents
促进细胞活化的外用剂 Download PDFInfo
- Publication number
- CN1240392C CN1240392C CNB031088236A CN03108823A CN1240392C CN 1240392 C CN1240392 C CN 1240392C CN B031088236 A CNB031088236 A CN B031088236A CN 03108823 A CN03108823 A CN 03108823A CN 1240392 C CN1240392 C CN 1240392C
- Authority
- CN
- China
- Prior art keywords
- cell
- skin
- external agent
- cell activation
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000020411 cell activation Effects 0.000 title claims description 15
- 230000001737 promoting effect Effects 0.000 title 1
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 229920002000 Xyloglucan Polymers 0.000 claims abstract description 13
- 108010001062 polysaccharide-K Proteins 0.000 claims abstract description 12
- 229920001543 Laminarin Polymers 0.000 claims abstract description 11
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 229920001491 Lentinan Polymers 0.000 claims abstract description 7
- 229940115286 lentinan Drugs 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 12
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims description 10
- 239000005717 Laminarin Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229920001503 Glucan Polymers 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 13
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 10
- 210000000214 mouth Anatomy 0.000 abstract description 9
- 208000003265 stomatitis Diseases 0.000 abstract description 7
- 230000001413 cellular effect Effects 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 210000004761 scalp Anatomy 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract 2
- 229920002307 Dextran Polymers 0.000 abstract 1
- 229920001218 Pullulan Polymers 0.000 abstract 1
- 239000004373 Pullulan Substances 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 abstract 1
- 235000019423 pullulan Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 26
- 238000011282 treatment Methods 0.000 description 18
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 16
- 206010048908 Seasonal allergy Diseases 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 15
- 210000004927 skin cell Anatomy 0.000 description 9
- 230000036039 immunity Effects 0.000 description 8
- 201000004384 Alopecia Diseases 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000035985 Body Odor Diseases 0.000 description 3
- 206010055000 Bromhidrosis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010067409 Trichophytosis Diseases 0.000 description 1
- 241001148683 Zostera marina Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- -1 glucosan and glucose Chemical class 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002113217A JP3885204B2 (ja) | 2002-04-16 | 2002-04-16 | 細胞活性促進外用剤 |
JP2002113217 | 2002-04-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1451389A CN1451389A (zh) | 2003-10-29 |
CN1240392C true CN1240392C (zh) | 2006-02-08 |
Family
ID=29243346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031088236A Expired - Fee Related CN1240392C (zh) | 2002-04-16 | 2003-03-26 | 促进细胞活化的外用剂 |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP3885204B2 (ja) |
CN (1) | CN1240392C (ja) |
AU (1) | AU2003213370A1 (ja) |
HK (1) | HK1060048A1 (ja) |
TW (1) | TWI254639B (ja) |
WO (1) | WO2003086421A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005053841A (ja) * | 2003-08-05 | 2005-03-03 | Kyouto Biomedical Science:Kk | 皮膚外用剤 |
CN1285382C (zh) * | 2004-12-20 | 2006-11-22 | 凌沛学 | 含海藻糖和玻璃酸的鼻腔用药传递系统及其制备方法 |
DE102007052380A1 (de) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten |
JP5620168B2 (ja) * | 2010-06-30 | 2014-11-05 | Dsp五協フード&ケミカル株式会社 | キシログルカン−カチオン複合体及びそれを含有する安定化組成物 |
CN103239571B (zh) * | 2013-05-26 | 2014-09-03 | 广州市云桥生物科技有限公司 | 一种用于治疗斑秃的中药有效部位组合物及其制备方法 |
JP6313118B2 (ja) * | 2014-05-16 | 2018-04-18 | 株式会社Cac | IgE抑制剤 |
EP3355893A4 (en) * | 2015-09-29 | 2019-06-12 | Kimberly-Clark Worldwide, Inc. | SYNERGISTIC COMPOSITION FOR MAINTAINING A HEALTHY BALANCE OF THE MICROFLORE |
FR3064473B1 (fr) * | 2017-04-03 | 2021-02-12 | Basf Beauty Care Solutions France Sas | Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale |
BE1027425B1 (fr) * | 2019-07-01 | 2021-02-08 | Aquilon Pharmaceuticals | Composition inhalable comprenant de la cyclodextrine a utiliser dans le traitement d’inflammations nasales |
WO2023060613A1 (zh) * | 2021-10-16 | 2023-04-20 | 南通市巨久新材料科技有限公司 | 一种含有云芝多糖包被层的外周血单个核细胞培养皿 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03204804A (ja) * | 1989-12-28 | 1991-09-06 | Mitsui Toatsu Chem Inc | 皮膚化粧料 |
JP2681527B2 (ja) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | 細胞活性促進外用剤 |
DE19710368A1 (de) * | 1997-03-13 | 1998-09-17 | Henkel Kgaa | Verwendung von wasserlöslichen beta-Glucanen als Wirkstoffe zur Herstellung von therapeutischen Mitteln zur Hautbehandlung |
JP2002275046A (ja) * | 2001-03-23 | 2002-09-25 | Kanebo Ltd | 表皮透過バリア強化剤及び皮膚外用組成物。 |
-
2002
- 2002-04-16 JP JP2002113217A patent/JP3885204B2/ja not_active Expired - Lifetime
-
2003
- 2003-02-20 TW TW092103549A patent/TWI254639B/zh not_active IP Right Cessation
- 2003-03-05 AU AU2003213370A patent/AU2003213370A1/en not_active Abandoned
- 2003-03-05 WO PCT/JP2003/002536 patent/WO2003086421A1/ja active Application Filing
- 2003-03-26 CN CNB031088236A patent/CN1240392C/zh not_active Expired - Fee Related
-
2004
- 2004-04-23 HK HK04102877A patent/HK1060048A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2005289815A (ja) | 2005-10-20 |
JP3885204B2 (ja) | 2007-02-21 |
CN1451389A (zh) | 2003-10-29 |
TW200407154A (en) | 2004-05-16 |
HK1060048A1 (en) | 2004-07-30 |
WO2003086421A1 (fr) | 2003-10-23 |
AU2003213370A1 (en) | 2003-10-27 |
TWI254639B (en) | 2006-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1240392C (zh) | 促进细胞活化的外用剂 | |
Namba | Maitake D-fraction: healing and preventive potential for cancer | |
CN102488278A (zh) | 一种具有双功能保健作用的复合真菌营养液 | |
US7897161B2 (en) | External medicine for treating dermatitis | |
CN105030812A (zh) | 一种复合真菌多糖胶囊 | |
CN1660442A (zh) | 含海藻糖和透明质酸的烧伤用药传递系统及其制备方法 | |
CN1615889A (zh) | 一种治疗皮肤病的药物 | |
WO2009022221A2 (en) | Composition and method to stimulate growth and defense against pathogens in plants | |
CN1177044C (zh) | 萝卜几丁质结合蛋白及其制备方法 | |
JP2004010605A (ja) | 脱アセタールと脱酸素橋化を行った茸類と発酵霊芝胞子に他の混合物を使った癌予防健康食品と制癌剤及び添加飼料 | |
US5786343A (en) | Phagocytosis activator compositions and their use | |
CA2485449A1 (en) | Method for preventing mucositis during cancer therapy | |
JP3890563B2 (ja) | パーマネントウェーブ剤 | |
CN1613876A (zh) | 一种具有抗肿瘤活性的三螺旋香菇多糖及其制法和用途 | |
CN108785496A (zh) | 一种口腔溃疡缓释贴膜及其制备方法 | |
US20060079481A1 (en) | Method of treating/preventing mucositis | |
CN1669472A (zh) | 野山菌保健品及其制备方法 | |
CN1075377C (zh) | 复合甘露聚糖肽口服液 | |
CN106729672A (zh) | 一种治疗上呼吸道黏膜炎的组合物及其应用 | |
CN1425691A (zh) | 乙酰甘露聚糖及其制备方法和应用 | |
CN1504191A (zh) | 葫芦素脂质体组方及其制剂 | |
CN1715297A (zh) | 松杉灵芝蛋白多糖及其制备方法与应用 | |
CN1715277A (zh) | 一种用于治疗心脑血管疾病的化合物及其制备方法和其在制药领域中的应用 | |
AU2004218698B2 (en) | Method | |
CN106692201A (zh) | 一种防治放射性口腔粘膜炎的组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1060048 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060208 |